A Randomized Double-Blind Placebo-Controlled Phase 3 Study of AKCEA-APOCIII-LRx Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)

Brief description of study

The purpose of this research study is to see if an investigational drug known as ISIS 678354 may help lower the risk of developing pancreatitis and to improve other symptoms of Familial Chylomicronemia Syndrome FCS by decreasing high triglyceride levels. FCS is a disease passed on through families. People with FCS have high amounts of fats called triglycerides (TG) and chylomicrons in their blood.


Clinical Study Identifier: s20-01668
ClinicalTrials.gov Identifier: NCT04568434
Principal Investigator: Ira J Goldberg.
Other Investigator: Akankasha Goyal.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.